Table One (IMAGE)
Caption
Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC), where information has previously been lacking despite being the age group most commonly affected.
Credit
© European Society for Medical Oncology
Usage Restrictions
To be used with the appropriate caption or credit
License
Licensed content